Menarini’s ASCO 2026 ELEVATE data raise bigger question on oral oncology combinations
Menarini’s elacestrant strategy is shifting from monotherapy to combinations. Can ELEVATE data support a broader breast cancer role?
ASCO 2026: Menarini’s elacestrant program expands the fight against endocrine resistance
Find out how Menarini’s elacestrant data at ASCO 2026 could reshape ER-positive metastatic breast cancer treatment.
Why AstraZeneca’s TRUQAP ODAC vote could reshape PTEN-deficient prostate cancer treatment
TRUQAP has ODAC support, but toxicity and survival maturity still matter. AstraZeneca’s prostate cancer expansion now faces FDA’s final test.